Press coverage about Prima BioMed (NASDAQ:PBMD) has been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Prima BioMed earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 43.1759974498271 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
PBMD has been the topic of several research analyst reports. Maxim Group set a $7.00 price objective on shares of Prima BioMed and gave the company a “buy” rating in a report on Monday, June 5th. Zacks Investment Research upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Wednesday, May 3rd.
Shares of Prima BioMed (PBMD) opened at 1.61 on Friday. The stock’s market capitalization is $33.48 million. Prima BioMed has a one year low of $0.51 and a one year high of $3.26. The company has a 50-day moving average of $1.67 and a 200 day moving average of $2.23.
WARNING: This news story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/08/27/prima-biomed-pbmd-earns-daily-media-impact-rating-of-0-13.html.
About Prima BioMed
Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.
Receive News & Ratings for Prima BioMed Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
